Destiny-Gastric03: T-Dxd In Her2+ And Her2-Low Gastric Cancer

DESTINY-Gastric03: T-DXd in HER2+ and HER2-low gastric cancer

DESTINY-Gastric02: 2L T-DXd in HER2+ gastric cancers

DESTINY-Gastric03: trastuzumab deruxtecan in HER2-overexpressing gastric cancer

DESTINY-Breast04: T-DXd for patients with HER2-low mBC

DESTINY-Gastric02: T-Dxd as a second-line treatment for HER2-positive gastric cancer

Updated analysis of DESTINY-Gastric02: T-DXd in HER2+ GEJ cancer who progressed with trastuzumab

DEBBRAH: T-DXd in HER2+ or HER2-low advanced breast cancer with CNS involvement

Updated results of DESTINY-Breast03: T-DXd vs T-DM1 in metastatic HER2+ breast cancer

Considerations for molecular testing for HER2+ gastric cancer

DESTINY-Breast03: T-DXd is superior to T-DM1 in HER2+ metastatic breast cancer

DESTINY-Breast04: T-DXd provides significant improvement in OS + PFS in HER2-low mBC

DESTINY-Breast02: T-DXd in HER2+ metastatic breast cancer previously treated with T-DM1

Dr Curigliano on the Efficacy of T-DXd in HER2-Low and HER2-Ultralow Breast Cancer

Advances in HER2-targeted therapies for gastric cancer

Safety follow-up of the randomized, phase 3 study DESTINY-Breast03

DESTINY-Breast03: safety follow-up results

Highlights from ESMO: DESTINY-Breast03

Updates from DESTINY-Gastric 01

Highlights on T-DXd in pretreated HER2-expressing solid tumours : The DESTINY-PanTumor02 study

European Society for Medical Oncology (ESMO)

DESTINY-Breast04: A ground-breaking trial in HER2-low breast cancer